<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00006466</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000068280</org_study_id>
    <secondary_id>LIFETIME-LTP-99-01</secondary_id>
    <secondary_id>LIFETIME-IRB-0300203</secondary_id>
    <nct_id>NCT00006466</nct_id>
  </id_info>
  <brief_title>Beta Alethine in Treating Patients With Myeloma</brief_title>
  <official_title>Phase I/II Study to Assess the Safety and Efficacy of Low Doses of Beta LT in Patients With Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LifeTime Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Biological therapies such as beta alethine use different ways to stimulate the&#xD;
      immune system and stop cancer cells from growing.&#xD;
&#xD;
      PURPOSE: Phase I/II trial to study the effectiveness of beta alethine in treating patients&#xD;
      who have myeloma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the antitumor effects of low-dose beta alethine in patients with myeloma or&#xD;
           progressive monoclonal gammopathy of undetermined significance.&#xD;
&#xD;
        -  Determine the effects of this regimen on anemia, performance status, pain, and&#xD;
           delayed-type hypersensitivity (immune response) in these patients.&#xD;
&#xD;
        -  Determine the safety of this regimen in these patients.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
      Patients receive beta alethine subcutaneously every 2 weeks for 6 doses. At day 85, patients&#xD;
      may receive an additional 12-week course of therapy in the absence of disease progression or&#xD;
      unacceptable toxicity. Patients with an apparent complete response receive additional&#xD;
      courses.&#xD;
&#xD;
      Patients are followed for 2 weeks.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 13-37 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>August 2000</start_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Multiple Myeloma and Plasma Cell Neoplasm</condition>
  <condition>Precancerous Condition</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>beta alethine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically proven myeloma&#xD;
&#xD;
               -  Multiple myeloma&#xD;
&#xD;
               -  Indolent myeloma with slowly progressive bone pathology&#xD;
&#xD;
               -  Smoldering myeloma with no bone pathology but a progressive increase in M-protein&#xD;
&#xD;
               -  Solitary myeloma OR&#xD;
&#xD;
          -  Diagnosis of evolving monoclonal gammopathy of undetermined significance with&#xD;
             increasing M-protein or decreasing hemoglobin level&#xD;
&#xD;
          -  Measurable M-protein or Bence Jones protein&#xD;
&#xD;
          -  Indolent disease not requiring therapy allowed&#xD;
&#xD;
          -  No clinical signs or evidence of active brain involvement or leptomeningeal disease&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  Karnofsky 50-100%&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  At least 4 months&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  Neutrophil count at least 1,500/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
          -  Hemoglobin at least 10 g/dL&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin less than 2.0 mg/dL&#xD;
&#xD;
          -  Transaminases no greater than 2.5 times upper limit of normal&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine no greater than 2.0 mg/dL&#xD;
&#xD;
          -  Creatinine clearance at least 60 mL/min&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  No acute changes on electrocardiogram&#xD;
&#xD;
          -  No uncontrolled angina, heart failure, or arrhythmia&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Adequate nutritional status (total protein at least 60.0 g/L, albumin at least 35 g/L)&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  No AIDS&#xD;
&#xD;
          -  No active bacterial infection (e.g., abscess) or with fistula&#xD;
&#xD;
          -  No history of alcoholism, drug addiction, or psychotic disorders that would preclude&#xD;
             study&#xD;
&#xD;
          -  No other nonmalignant disease that would preclude study&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  At least 4 weeks since prior immunotherapy or cytokines&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas, mitomycin, or&#xD;
             high-dose carboplatin)&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  No concurrent corticosteroids&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  No prior radiotherapy to greater than 25% of bone marrow&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  Recovered from any prior surgery&#xD;
&#xD;
          -  No prior solid organ transplantation&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No other concurrent investigational agent&#xD;
&#xD;
          -  No concurrent immunosuppressive agents&#xD;
&#xD;
          -  No concurrent anti-inflammatory agents, including aspirin or over-the-counter or&#xD;
             prescription nonsteroidal anti-inflammatory drugs&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Suzin Mayerson, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>LifeTime Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Emory Clinic</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Victory Over Cancer</name>
      <address>
        <city>Rockville</city>
        <state>Maryland</state>
        <zip>20852</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Vincents Comprehensive Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10011</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2002</verification_date>
  <study_first_submitted>November 6, 2000</study_first_submitted>
  <study_first_submitted_qc>October 7, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 8, 2003</study_first_posted>
  <last_update_submitted>December 17, 2013</last_update_submitted>
  <last_update_submitted_qc>December 17, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 18, 2013</last_update_posted>
  <keyword>monoclonal gammopathy of undetermined significance</keyword>
  <keyword>isolated plasmacytoma of bone</keyword>
  <keyword>extramedullary plasmacytoma</keyword>
  <keyword>refractory multiple myeloma</keyword>
  <keyword>stage I multiple myeloma</keyword>
  <keyword>stage II multiple myeloma</keyword>
  <keyword>stage III multiple myeloma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Plasmacytoma</mesh_term>
    <mesh_term>Precancerous Conditions</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

